Difference between revisions of "TF Actinium"
(→Ac-225) |
|||
| Line 12: | Line 12: | ||
https://phys.org/news/2018-06-scientists-actinium-rare-medical-radioisotope.html | https://phys.org/news/2018-06-scientists-actinium-rare-medical-radioisotope.html | ||
| + | |||
| + | DOE IP is focused on Ac-225, but its production via limited to the amount of Th-229 on hand (so called Thorium cow). So we are also pursuing accelerator based production (mostly proton machines, but also some photo-nuclear reactions). The proton machines also generates comparable amount of Ac-227 which is problematic due to its long lifetime. | ||
==Ac-226== | ==Ac-226== | ||
Revision as of 04:28, 22 July 2020
Current production facilities
Ac-225
An alpha emitter for Cancer Therapy
made at : BNL (BLIP), LANL (IPF), ORNL
https://phys.org/news/2018-06-scientists-actinium-rare-medical-radioisotope.html
DOE IP is focused on Ac-225, but its production via limited to the amount of Th-229 on hand (so called Thorium cow). So we are also pursuing accelerator based production (mostly proton machines, but also some photo-nuclear reactions). The proton machines also generates comparable amount of Ac-227 which is problematic due to its long lifetime.
Ac-226
Single neutron knockout of Ra-226 goes to Ra-225 which decays to Ac-226 after 14 days. Ac-226 is a beta emitter with a half life of 29 hours.
Ac-227 (Cancer Therapy)
ORNL (HFIR)
Ac-227 is presently produced by the DOE IP to be incorporated into the Bayer Xofigo drug, where the mode of interest is that Ac-227 -> Ra-226 which eventually emits an alpha (Ra-226 generators). so the beta emission is not what drives its use as a cancer therapy, the resulting alpha from the Ra-226 is what makes it useful.